QTRX
Quanterix Corp

1,102
Mkt Cap
$313.9M
Volume
381,052.00
52W High
$8.77
52W Low
$4.05
PE Ratio
-2.88
QTRX Fundamentals
Price
$6.55
Prev Close
$6.72
Open
$6.57
50D MA
$6.57
Beta
1.72
Avg. Volume
776,072.25
EPS (Annual)
-$1.00
P/B
1.00
Rev/Employee
$291,764.33
$156.09
Loading...
Loading...
News
all
press releases
Curaleaf Holdings, Inc. (CURLF) Reports Q4 Loss, Tops Revenue Estimates
Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of +35.48% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
More News
News Placeholder
Quanterix to Participate in Upcoming Investor Conferences
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will...
Business Wire·1d ago
News Placeholder
Envestnet Asset Management Inc. Grows Holdings in Quanterix Corporation $QTRX
Envestnet Asset Management Inc. boosted its position in Quanterix Corporation (NASDAQ:QTRX - Free Report) by 122.7% during the third quarter, according to its most recent 13F filing with the...
MarketBeat·2d ago
News Placeholder
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on...
Business Wire·7d ago
News Placeholder
Quanterix (NASDAQ:QTRX) Shares Up 0.7% - Time to Buy?
Quanterix (NASDAQ:QTRX) Trading Up 0.7% - Should You Buy...
MarketBeat·9d ago
News Placeholder
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
QTRX submits a 510(k) to the FDA for its multi-analyte blood test aimed at evaluating cognitive symptoms for possible Alzheimer's disease.
Zacks·23d ago
News Placeholder
Quanterix Submits FDA 510(k) For Multi-Analyte Blood Test For Alzheimer's Disease
(RTTNews) - Quanterix Corporation (QTRX) on Tuesday said it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test to...
Nasdaq News: Markets·24d ago
News Placeholder
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimers Disease Detection
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket...
Business Wire·24d ago
News Placeholder
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimers Risk Profiling
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the...
Business Wire·1mo ago
News Placeholder
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on...
Business Wire·1mo ago
<
1
2
...
>

Latest QTRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.